schizophrenia outside hospital (Crumpton, 1968; Rassmussen, 1970; Daniel, 1968; Johnson and Freeman, 1972) Goldberg et al., 1967) and long-acting injections are as effective as oral medication for long-stay patients (Kinross-Wright and Charalampous, 1965; Bankier et al., 1968; Haider, 1968; Van Praag et al., 1970) . The opinion that long-acting phenothiazines are better than oral medication for schizophrenic patients outside hospital is based on findings that patients have had fewer admissions to and a shorter total duration of stay in hospital after starting fluphenazine injections than during an equivalent period of time before (Rassmussen, 1970; Denham and Adamson, 1971 ; Johnson and Freeman, 1972) . "Mirror image" studies have been criticized for their methodological shortcomings (Blackwell and Shepherd, 1968) , and for this and other reasons these studies were inconclusive.
In the absence of a fully satisfactory investigation of longacting phenothiazines the present study was carried out to decide the following questions: (1) In the setting of a special clinic for chronic schizophrenic outpatients already established on long-acting medication is fluphenazine decanoate significantly more effective than placebo injections? (2) Does it prevent specifically schizophrenic symptoms or only moderate other forms of behaviour? (3) Are the risks of depression and Parkinsonian symptoms greater in patients on long-acting phenothiazines?
The decanoate form of fluphenazine was studied because its action, though similar to fluphenazine enanthate, is allegedly more prolonged (Kurland and Richardson, 1966; Bucci et al., 1970 of intake into the study. The criteria for selection included: current age 15-67, age of onset 10-60, positive evidence of schizophrenia in the case records, chronicity indicated by two or more admissions to hospital or one admission lasting more than six months, and maintenance on a minimum monthly dose of fluphenazine decanoate of 25 mg begun at least eight weeks before beginning the trial and without supplementary ataractic medication.
St. Olave's is a general hospital serving the northern part of the London Borough of Southwark, a stable working-class area in the heart of dockland with a population of 90,000. Clinical policy for five years preceding the study had been to treat all relapsed schizophrenic outpatients with long-acting phenothiazines in a special clinic run by two nursing sisters, who visited patients at home if they failed to come for injections. Since the unit has been put forward as a model for helping patients in the community with a low bed-per-population ratio (Oldham, 1969) , the patients may be fairly assumed to be representative of the schizophrenic outpatients in the area.
To increase our sample a second, Patients began the trial at the time of their usual clinical appointment, when they were seen by one of three research psychiatrists (S.R.H., R.G., P.R.) and tested by the Present State Examination (P.S.E.) (9th edition), the M.R.C. Social
Performance Schedule (Leff and Vaughn, 1972; Stevens, 1972; Wing et al., 1972) , and the Events Schedule of Brown and Birley (1970) . A relative or close informant was independently interviewed by the sociologist member of the team to measure the effects on functioning and attitudes and to provide an additional source of information about the patient (Stevens, 1973) . Initial interviews were apportioned equally among the research psychiatrists, and in most cases they saw the same patients throughout.
The interviews were repeated if a patient was taken out of the trial, or dropped out, or was admitted to hospital. All patients were re-evaluated nine months after they entered the trial.
CRITERION FOR RELAPSE
The null hypothesis that there was no difference between active drug and placebo was tested by a single criterion for relapse-namely, a decision by the hospital's clinical team that a patient's condition had so deteriorated that he or she must be taken out of the trial to ensure that active medication was prescribed. Patients could be admitted to hospital and/or receive antidepressant or anti-Parkinsonian medication without being taken out of the trial, but the research evaluations were repeated on each admission and any additional medication was recorded. Patients prescribed oral phenothiazines were taken out of the trial (treated as a relapse).
Attending clinicians were asked not to take patients out of the trial unless their schizophrenic symptoms worsened. Patients admitted to hospital but not removed from the trial were taken out of it if one of the research team found a clear-cut increase in symptoms since the initial evaluation. This, together with the fact that one of the research team (R.G.) was also in clinical charge of the St. Olave's patients during the trial, meant that clinical evaluation was independent of research evaluation in about two-thirds of the patients. Rules were set up to deal with special cases.
INITIAL COMPARISON OF GROUPS
Initial comparisons between the active drug and placebo groups on 22 social and clinical variables are shown in tables II and III. All 81 patients who entered the trial were included but a patient was omitted from any item of comparison when the information on the matter was incomplete or inadequate. Using 2 by 2 contingency tables (Finney et al., 1963) or Student's t test where appropriate there was no significant difference between experimental and control groups in any of the 22 comparisons tested.
The social variables ( tThirty-six patients in the experimental group had 9,309 days at risk or 1-53 times the risk before relapsing or completing the trial as compared with 38 patients on placebo who had 6,062 days at nsk. Correcting for this would make the difference non-significant. N.S. = Not significant.
MEASURES OF RELAPSE COMPARED
The repeat interview in the case of all patients taken out of the trial because of relapse gave an opportunity for a research re-evaluation of the patient's condition at relapse, compared to their clinical and social state at the onset of the trial, and compared with the clinician's decision that the patient had relapsed. This was advisable since there was some contamination between the two measurements, because research workers knew when a patient had been taken out of the trial. In 24 cases at initial interviews and six at relapse the clinician in charge of the patient also undertook the P. who were switched to placebo. More importantly, the relapse rate among patients who continued on active medication was only 8% over 9 months and 14-17% over 13 months -remarkably low. Trials of treatment in psychiatry might usefully consider more often group prognosis in patients undergoing a particular treatment. To do this properly a trial should be epidemiologically based, so that knowledge of all patients from the catchment area could be used to show which were chosen for a given treatment and which were not and how many defaulted from the original group. By then following up all patients an estimate of the response rate to any particular treatment could be obtained (Leff and Wing, 1971) .
Our data can be used to estimate the proportion of schizophrenic patients who can be expected to present management problems on long-acting fluphenazine over 15 months. During the nine months of the trial and six month follow-up 5-6 patients (14-17%) relapsed. Of the original St. Olaves catchment area based sample eight patients (10%) had been excluded for reasons reflecting unsuccessful management despite long-acting fluphenazine (table 1) (Stevens, 1973) , but in most cases it was associated with an exacerbation of schizophrenic symptoms. We therefore conclude that fluphenazine decanoate has a powerful effect in preventing and ameliorating both schizophrenic symptoms and deterioration of behaviour and social functioning.
We have stated that we cannot accept the 8% relapse rate of our experimental group at face value. Ninety-five per cent. of our sample had been established on treatment more than three months and most more than a year, so that patients who had been negative responders, relapsed or lapsed from treatment would have been omitted from the sample. Thus the proportion of chronic schizophrenics who relapsed and began treatment with fluphenazine decanoate but were unlikely to remain well-controlled for a year might be expected to be more than 30%, in contrast to patients well established on treatment, of whom only 8% relapsed during nine months in this trial.
It is noteworthy that 89% of patients entering our trial received just one 25-mg injection of fluphenazine decanoate monthly. Some centres give much higher doses, but these findings suggest that low doses are effective in most cases.
This study has not touched on the problems of the chronic disabilities of these patients. With the greater control of florid symptoms which treatment provides the management of residual disability will become an increasing problem, because of the growing number of chronic patients returning to live in the community.
Introduction
During the past four years we have noticed that patients with endemic skeletel fluorosis often show radiological bone changes, such as coarse cystic trabeculation and sub periosteal phalangeal resorption. These observations, coupled with reports in the literature of resorption cavities in animal experimental fluorosis (De Senar Clens, 1941; Rockert and Sunzel, 1960; Rockert, 1963) suggested to us the possibility of hyperactivity of the parathyroid glands in patients with skeletal fluorosis. The present study was therefore undertaken to investigate the pathogenetic role of the parathyroids in patients with skeletal fluorosis.
Subjects and Methods
Twenty patients (17 men and 3 women) aged 42 to 68 years with proved endemic skeletal fluorosis were investigated for
